US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Moderna, Inc. - Common Stock (NQ:MRNA)

225.00 +28.00 (+14.21%)
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy? ↗
Additional blockbuster drugs may be on the horizon. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Why Moderna (MRNA) Stock Is Trading Up Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 2.6% in the afternoon session after the European Commission signed a contract to ... 
Via StockStory
News headline image
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
From Moderna, Inc.
Via ACCESS Newswire
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
Gapping S&P500 stocks in Wednesday's session ↗
Via Chartmill
Wednesday's pre-market session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Moderna Appoints Michael McDonnell to Board of Directors
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Stock Is Soaring. Is It Too Late to Buy? ↗
Moderna's growth story is just beginning. 
Via The Motley Fool
News headline image
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More ↗
These stocks have jumped in the double- and triple-digits. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
Stay informed with the top movers within the S&P500 index on Monday. ↗
Via Chartmill
Monday's pre-market session: top gainers and losers in the S&P500 index ↗
Via Chartmill
Wall Street Got the Weak Jobs Report It Wanted. Chip Stocks Wrecked the Rally Anyway. ↗
Via Chartmill
News headline image
MarketBeat Week in Review – 06/29 - 07/03 ↗
MarketBeat's weekly roundup covers a weaker June jobs report, tech sector rotation, and top analyst picks including TSLA, AVGO, PLTR, MRNA, and NEE heading into Q2 earnings season. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives? ↗
When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong. 
Via The Motley Fool
News headline image
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? ↗
Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles. 
Via The Motley Fool
News headline image
3 Cash-Heavy Stocks with Warning Signs
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
Via StockStory
Topics Artificial Intelligence
News headline image
Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its pe... 
Via StockStory
Topics Artificial Intelligence
Thursday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
Short Squeeze Alert—Moderna Stock Surges on New Strategy ↗
Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines faces a multi-year path to revenue. 
Via MarketBeat
News headline image
Is Moderna Stock a No-Brainer Buy After a Key FDA Win? ↗
Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock. 
Via The Motley Fool
News headline image
Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers. ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over th... 
Via StockStory
Topics Artificial Intelligence
Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side ↗
Via Chartmill
Discover which S&P500 stocks are making waves on Friday. ↗
Via Chartmill
Friday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst ↗
It's not just a "pandemic stock," after all. 
Via The Motley Fool
News headline image
Moderna Science Day Highlights Expanding Potential of mRNA Platform
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >